**Name of Journal:** *World Journal of Transplantation*

**Manuscript NO:** 65325

**Manuscript Type:** MINIREVIEWS

**Extracorporeal membrane oxygenation in lung transplantation: indications, techniques and results**

Faccioli E *et al*. ECMO and lung transplantation

Eleonora Faccioli, Stefano Terzi, Alessandro Pangoni, Ivan Lomangino, Sara Rossi, Andrea Lloret, Giorgio Cannone, Carlotta Marino, Chiara Catelli, Andrea Dell'Amore

**Eleonora Faccioli, Stefano Terzi, Alessandro Pangoni, Ivan Lomangino, Sara Rossi, Andrea Lloret, Giorgio Cannone, Carlotta Marino, Chiara Catelli, Andrea Dell'Amore,** Thoracic Surgery Unit, Department of Cardiothoracic and Vascular Sciences, University of Padova, Padova 35128, Italy

**Author contributions:** Faccioli E, Dell'Amore A contributed to conceptualization and writing, Terzi S, Pangoni A designed the research study; Lomangino I, Loret A performed the research; Rossi S, Carlotta M Catelli C contributed to review analysis; Cannone G, edited the manuscript; all authors have read and approved the final manuscript.

**Corresponding author: Andrea Dell'Amore, MD, Professor,** Thoracic Surgery Unit, Department of Cardiothoracic and Vascular Sciences, University of Padova, Via G Verci 8, Padova 35128, Italy. andrea.dellamore@unipd.it

**Received:** March 4, 2021

**Revised:** April 13, 2021

**Accepted:** May 25, 2021

**Published online:** July 18, 2021

**Abstract**

The use of extracorporeal membrane oxygenation (ECMO) in the field of lung transplantation has rapidly expanded over the past 30 years. It has become an important tool in an increasing number of specialized centers as a bridge to transplantation and in the intra-operative and/or post-operative setting. ECMO is an extremely versatile tool in the field of lung transplantation as it can be used and adapted in different configurations with several potential cannulation sites according to the specific need of the recipient. For example, patients who need to be bridged to lung transplantation often have hypercapnic respiratory failure that may preferably benefit from veno-venous (VV) ECMO or peripheral veno-arterial (VA) ECMO in the case of hemodynamic instability. Moreover, in an intra-operative setting, VV ECMO can be maintained or switched to a VA ECMO. The routine use of intra-operative ECMO and its eventual prolongation in the post-operative period has been widely investigated in recent years by several important lung transplantation centers in order to assess the graft function and its potential protective role on primary graft dysfunction and on ischemia-reperfusion injury. This review will assess the current evidence on the role of ECMO in the different phases of lung transplantation, while analyzing different studies on pre, intra- and post-operative utilization of this extracorporeal support.

**Key Words:** Lung transplantation; Extracorporeal membrane oxygenation; Bridge to transplantation; Support; Primary graft dysfunction; Ischemia-reperfusion injury

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Faccioli E, Terzi S, Pangoni A, Lomangino I, Rossi S, Lloret A, Cannone G, Marino C, Catelli C, Dell'Amore A. Extracorporeal membrane oxygenation in lung transplantation: indications, techniques and results. *World J Transplant* 2021; 11(7): 290-302

**URL:** https://www.wjgnet.com/2220-3230/full/v11/i7/290.htm

**DOI:** https://dx.doi.org/10.5500/wjt.v11.i7.290

**Core Tip:** Extracorporeal membrane oxygenation (ECMO) is the most used support in lung transplantation as it allows a complete spectrum of support (blood oxygenation, decarboxylation and cardiocirculatory support). Due to its versatility it can be used in a pre-operative setting (bridge to transplantation) and might be prolonged intra- and/or post-operatively. All these factors, in combination with a growing experience in its use in lung transplantation, usually in a multidisciplinary team, has resulted in good outcomes derived from several experiences reported in the literature by high-volume transplant centers. This paper aims to systematically review current evidence on pre, intra and post-operative ECMO in lung transplantation.

**INTRODUCTION**

Lung transplantation (LTx) is an established option for patients with an end-stage lung disease unresponsive to any medical option. Despite some significant advances in medical therapy and in the organ allocation policy, such as the introduction of the lung allocation score (LAS) in 2005[1], the number of patients on the waiting list far exceeds the number of available organs, consequently the mortality remains high.

The LAS score effectively prioritized the candidacy of the sickest patient[2,3] and for this reason, in the past decades, there has been an increasing number of acute patients across transplant centers and a more frequent use of bridging support strategies, such as mechanical ventilation and extracorporeal membrane oxygenation (ECMO). Since then, in several transplantation centers, ECMO is routinely offered to patients with a rapidly declining end-stage disease as a bridging strategy to transplantation or, in the case of instability or inadequate graft function, as intra- and/or post-operative support. No randomized trials have ever been conducted to validate which one of these indications is the best; therefore, the preferred indication is for its utilization needs to be adapted on the single center’s experience and on the patient’s clinical conditions.

Recently, given the strong interaction between multidisciplinary teams and the increased experience in its use and in patient selection, ECMO is being extensively utilized in high-volume lung transplant centers[4] with good results[5,6].

Different configurations of ECMO, shown in Table 1, can be applied in LTx depending on the required support.

***Veno-venous ECMO***

Veno-venous (VV) ECMO is used in refractory respiratory failure and requires the placement of peripheral catheters. Usually, deoxygenated blood is drained from the femoral catheter and, after oxygenation, it is returned *via* the jugular vein. This configuration has no impact on cardiac function. In LTx, it can be used in patients, who do not present with significant hemodynamic compromise, with hypercapnic respiratory failure (low flow) or with significant hypoxia (full flow). This setting can be used as a bridge to LTx, especially in patients with end-stage pulmonary hypertension (PH), as it can increase right ventricular preload reducing the after-load and improving hematosis, and as a continuous support during transplantation. In a setting of bridging to lung transplant, the VV configuration is the most popular as it has several advantages compared to veno-arterial ECMO, for example, a lower rate of vascular and neurological complications. On the other hand, it provides only respiratory assistance without cardiac support (Figure 1A).

***Veno-arterial ECMO***

Veno-arterial (VA) ECMOis used for hemodynamic support with or without respiratory failure (Figure 1B). The cannulation can be performed centrally [drained from the right atrium and reinfused in the aorta (Figure 1C)] or peripherally (usually through femoral vessels). The use of bicaval venous cannulation has recently been described to configure a central VA ECMO in patients with severe cardiomegaly and pulmonary arterial hypertension in order to obtain optimal cardiac support and allow lung implantation without severe hemodynamic repercussions during cardiac manipulation (Figure 1D)[7]. Either central or peripheral VA ECMO can be used as intra LTx support, but the central setting has several advantages as it ensures a higher blood flow, by using a large inflow cannula with a large outflow cannula, avoiding peripheral ECMO-related issues (blood flow insufficiency, limb ischemia, vessel injury and groin infection). The peripheral VA configuration delivers oxygenated blood to the coronary arteries and brain *via* retrograde flow to the aortic arch. If left ventricular function improves, the retrograde flow will compete with the ventricular ejection; consequently, the coronary arteries and brain might be perfused with deoxygenated blood coming from the failing lungs and ejected from the left ventricle. On the other hand, peripheral ECMO is less invasive and it can be established under local anesthesia, it does not necessitate a clamshell incision and it can be maintained in the post-operative setting[8].

***Veno-arterial-venous ECMO***

Veno-arterial-venous (VAV) ECMO can also be used in LTx especially in the case of severe right heart dysfunction, providing both respiratory and circulatory support. In this support configuration, blood is drained from veins, oxygenated and returned to the right atrium and a central artery.

A variant of VAV configuration is the “sport model”[9]; it describes an optimal cannulation for VAV ECMO that uses a double lumen cannula VV ECMO configuration with additional oxygenation directly to the aortic arch. This technique allows cardiac and pulmonary resuscitation with a total gas exchange of perfused oxygenated blood to the proximal and distal aortic arch, and the weaning from VA and VV ECMO and ambulation in a setting of bridging to LTx[10].

Other devices used in LTx are:

**Interventional Lung Assist Novalung (Novalung, GmbH, Hechingen, Germany):** Thisis alow resistance lung assist device designed for a pulsatile blood flow with tight diffusion membranes and a protein matrix coating[11]. It does not require a pump assistance, as it is driven by cardiac output. In recent years, this device has been widely utilized as an effective bridge strategy to LTx in patients with ventilation-refractory hypercapnia[12-15].

**Extracorporeal carbon dioxide removal:** This is a sort of “respiratory dialysis”[7]. By using small percutaneous catheters, it is indicated to correct isolated hypercapnic failure in chronic obstructive pulmonary disease, cystic fibrosis (CF) or fibrosis exacerbations[16].

In this paper, we conduct a review to assess current evidence on the use of ECMO as a bridge to LTx, in the intra-operative setting and as post-operative support in the field of LTx.

**ECMO AS A BRIDGE TO LTx**

***General considerations***

The use of a mechanical pump-oxygenator to support a heart-LTx was first described by Webb and Howard at the end of 1950s and, between 1972 and 1977, many centers reported the use of extracorporeal oxygenators in patients who died awaiting LTx[17,18]. In 1977, the first successful case of ECMO as a bridge to LTx was reported by Vieth who described a patient with post-trauma respiratory failure who underwent bilateral LTx[19]; unfortunately, the patient survived for only 10 d. In 1982, another case of ECMO as a bridge to LTx for 19 d was reported in a patient successfully bridged to a single LTx with short-term outcome in terms of survival[20].

The first successful use of ECMO as a bridge to LTx was published by Jurmann *et al* in 1991[21]: They described the use of VA ECMO in two patients who developed severe primary graft dysfunction (PGD) after LTx and who underwent re-transplantation with ECMO support.

The selection of patients who can benefit from ECMO as a bridge to LTx is a crucial aspect: Highly urgent patients, with a predicted high pre-transplant mortality, are often the ones who would benefit the most from ECMO support but, at the same time, they represent the patients, which are too critical to be considered appropriate for ECMO. The guidelines of the International Society of Heart and Lung Transplantation report that extracorporeal life support should be recommended in the case of young age, absence of multiorgan dysfunction and good rehabilitation potential. On the other hand, ECMO is not indicated in the case of septic shock, multiorgan dysfunction, heparin-induced thrombocytopenia, obesity, severe arterial occlusive disease, advanced age, underlying irreversible neurological or neuromuscolar disease[22].

Patients who can derive the greatest benefit from ECMO bridge are those with cardiopulmonary dysfunction severe enough to limit their ability to maintain the necessary physical conditioning to tolerate a transplant, and, in general, it is recommended in patients who have already been evaluated as appropriate candidates for LTx[23].

After a patient is considered suitable for an ECMO bridge strategy, the circuit can be configured in multiple ways (such as VA, VV or VVA) with peripheral or central access, depending on the disease and pathophysiology of the patient, in order to provide the easiest management. It has to be taken into consideration that peripheral cannulation is the simplest approach to a bridge to LTx. For example, in patients affected by CF, a VV ECMO is usually sufficient to improve oxygenation and reduce blood concentration of CO2, whereas in the case of idiopathic pulmonary arterial hypertension VA ECMO represents the best choice.

***Current evidence on ECMO bridge***

An analysis reported by the United Network for Organ Sharing (UNOS) demonstrated a significant increase in recent years in the use of ECMO at the time of LTx, compared to previous decades (1970-2010). This finding is a direct consequence of the greater use of ECMO in patients awaiting LTx[24,25]. A study by Mason *et al*[26] reported a negative experience with ECMO bridge to LTx showing a worse survival in patients with ECMO support compared to unsupported patients (50% *vs* 79%). In more recent years, different authors reported experiences with the ECMO bridge with good outcomes in terms of percentage of successfully bridged patients and with satisfying survival rates. The outcomes of ten major studies on this topic are reported in Table 2. We decided to collect the most recent studies (published from 2017 to 2020) to provide updated evidence. As reported in Table 2, the median duration of ECMO bridge ranged from 2 d[27] to 17 d[28], the most frequently used configuration was VV ECMO[26-34] and the majority of patients were successfully bridged to transplantation. Biscotti *et al*[29] reported the lowest percentage of successfully bridged patients; on the other hand, two studies[27,30] had a 100% success rate with the ECMO bridge to transplantation. Various authors, as expected, reported post-operative bleeding as the most frequent complication[28,29,32,34,35] in the bridged patients. The reported in-hospital mortality was acceptable in the majority of the studies, except for Yeo *et al*[28] who had an in-hospital mortality rate of 42%, but it has to be taken in consideration that the clinical conditions of patients supported with pre-transplant ECMO are usually more critical than those of the general population waiting for a LTx not supported by ECMO. This may have a negative influence on their post-operative outcomes, increasing in-hospital mortality. Recently, better results have been published following maintenance of ECMO support with the patient awake to allow adequate physiotherapy training and avoid muscle deconditioning secondary to general anesthesia and prolonged curarization[4,36].

With regard to long-term survival, all the studies reported a satisfying 1-year (ranging from 57.9%[28] to 100%[27]) and 3-year (from 63%[34] to 83%[31]) survival rate. The outcomes of the studies listed in the table are difficult to compare as they represent different realities among centers from all over the world. Furthermore, the decision to use ECMO as a bridge to transplant in a specific patient is center-dependent and the maintenance of a patient’s candidacy to LTx while undergoing ECMO is also subject to institutional variation in risk assessment. Despite these considerations, the good outcomes reported lead us to consider ECMO a successful strategy as a bridge to LTx with the objective of improving the pre-operative condition of patients by enhancing physical strength and reducing cardiovascular complications[37].

Obviously, careful patient selection, center transplant volume and the multidisciplinary team are the key factors in obtaining improvement in outcomes of ECMO bridge. Further studies are needed to validate these results.

**ECMO IN THE INTRA-OPERATIVE SETTING**

***General considerations***

ECMO has been extensively used as a valid alternative to cardiopulmonary bypass (CPB) in LTx to provide hemodynamic and respiratory support during the surgical procedure. Different studies have compared ECMO to CPB demonstrating that ECMO resulted in fewer complications such as shorter duration of mechanical ventilation, shorter intensive care unit and hospital length of stay and reduced post-operative bleeding[38,39]. All patients who are bridged to transplant on ECMO usually remain on ECMO throughout the procedure. ECMO can also be used ex-novo during the surgical procedure in the case of hemodynamic instability and PH, which is associated with a higher risk of PGD, and may necessitate control over the pulmonary arterial pressure and lung reperfusion at the time of graft implantation[40]. Intra-operatively, VA ECMO is preferred over VV ECMO, as the latter does not ensure adequate cardiac output in patients with right ventricular dysfunction. Intra-operative VA ECMO support can be extended into the post-operative period or converted to VV ECMO in patients with good cardiac function for the management of PGD.

Various studies have recently proposed the routine use of intra-operative ECMO in LTx to allow controlled reperfusion and protective ventilation of the graft during transplantation, while reducing the ischemia-reperfusion injury and improving post-operative PGD rates[6,40-42]. On the other hand, we know that ECMO support can be associated with specific complications such as bleeding, reoperations, infections, and vascular damage that may affect post-operative results. Ius *et al*[4] suggested that, in order to minimize these complications, the identification of patients who really need intra-operative ECMO is necessary *a priori*. Moreover, the implantation of ECMO in urgent conditions (for example during or after a pneumonectomy) should be avoided.

***Current evidence on intra-operative ECMO***

During LTx, the implantation of ECMO is usually taken into consideration if there is worsening of cardiopulmonary conditions during the first or the second clamp of the pulmonary artery. Indications for intra-operative ECMO include a combination of the following conditions[4]: (1) Hypercapnia; (2) Low arterial saturation (< 90%); (3) Low cardiac index (< 2 L/min/m2); and (4) Significant increase in pulmonary pressure. Between 2017 and 2020, five studies reported detailed outcomes on the use of ECMO during LTx (Table 3)[41,43-46]*.* Central (c) ECMO is commonly used in the intra-operative setting. Glorion *et al*[43] reported that almost half of patients (47.5%) were assisted with peripheral (p) ECMO. They compared 54 patients who had cECMO to 49 patients who had pECMO and reported similar results between the two groups in terms of in-hospital death, long-term survival rates and number of chest re-openings, even though the pECMO group included more bridged patients, who received an emergency transplant and who were supposed to be in a more critical condition. The study by the Vienna Group[6], conducted on a larger cohort of patients, reported a 100% rate of the usage of cECMO in the intra-operative setting with superior results in survival, when compared to transplantation without any extracorporeal support. When considering the utilization of intra-operative ECMO, as for the ECMO bridge, the most frequent complication reported is bleeding requiring surgical revision (from 12%[46] to 35% of patients[4]). For this reason, the Hannover group[4] suggested the administration of half-dose protamine to antagonize the heparin effect.

Ius *et al*[4] reported a higher prevalence of major complications, a significantly higher PGD 2-3 rate and a worst overall survival in the ECMO group than in the no ECMO patients; similarly Cosgun *et al*[44] concluded their study with the assumption that LTx with intraoperative ECMO support is associated with poorer outcomes. In contrast to these findings, the Italian group[43] reported comparable outcomes between the two groups, despite a higher need for intra-operative transfusion in the ECMO population. Similarly, the Vienna group[6] reported a significant superior survival in the ECMO group without a significant difference in PGD rate between the two groups, but it is well known that the current PGD classification does not perfectly reflect the real graft function, as it is primarily based on chest radiography which may have many confounders.

Another important concept is the prophylactic intra-operative utilization of ECMO, introduced by the Vienna group[6] in 2018: If the transplantation is performed without ECMO support, the first implanted lung will be exposed to the full cardiac output with possible damage[44], which may lead to a higher rate of PGD. In this context, prophylactic intra-operative ECMO may provide optimal reperfusion by diverting a significant proportion of the cardiac output away from the lung. This evidence was also supported by their recent study[41] in which they have postulated that the routine application of intra-operative ECMO in all the patients, regardless of respiratory and hemodynamic conditions, improved graft function.

These findings on the routine use of intra-operative ECMO in LTx provide important considerations, but other studies on this topic will be necessary to validate these preliminary results.

**ECMO IN THE POST-OPERATIVE PERIOD**

***General considerations***

At the end of the transplant procedure, especially if arterial blood gas analysis and pulmonary arterial pressure are not satisfactory, ECMO can be prolonged in the post-operative period. Post-operative prolongation of ECMO is mandatory in patients with PH and in patients with questionable graft function at the end of transplantation. In the post-operative setting, ECMO can also be implanted ex novo in the case of hemodynamic instability or inadequate graft function. PGD, a form of acute lung injury characterized by infiltrates on chest X ray and an impairment in blood gas exchange, is one of the leading causes of death in the early post-transplant course[47,48]. The use of ECMO during the post-operative period may reduce the PGD grade by supporting gas exchanges and pulmonary hemodynamics, while reducing ventilator-associated lung injury in acute distress syndrome. Moreover, it provides support for patients with refractory hypoxemia or right ventricular failure, caused by severe PGD, by facilitating the use of a lung protective ventilation strategy[49,50]. Two different studies have demonstrated that early implantation of secondary ECMO in the case of PGD provides better results than later implantation[49,51]. In addition to this, several groups have recently demonstrated that pulmonary edema occurring in PGD is mainly related to diastolic dysfunction of the left ventricle than to right ventricle stress[4,52-55]. This consideration suggests that the implantation of a secondary VA ECMO or the prolongation of ECMO (particularly in the case of PH) may lead to excellent results by allowing controlled filling and recovery of the left ventricle, preventing an acute increase in venous pressure hence reducing the reperfusion injury causing the PGD[56]. For this reason, particularly in this subgroup of patients, the use of ECMO in the post-operative setting may be considered a routine procedure[6].

***Current evidence on post-operative ECMO***

Studies on the use of post-operative ECMO and outcomes are presented in Table 4. Mulvihill *et al*[57], in their study on de-novo ECMO based on the UNOS registry, reported the utilization of post-transplant ECMO in 5.1% of cases. They found that ischemic time and pre-transplant ECMO were statistically associated with the need for post-operative ECMO 72 h after transplantation; this evidence supports a direct role of prolonged ischemic time in the pathogenesis of PGD, as reported by other studies[58-60]. Hoetzenecker *et al*[6] extensively investigated the concept of prophylactic post-operative ECMO prolongation, particularly in patients with PH and with questionable graft function (oxygen tesion/inspired oxygen fraction > 100, mean pulmonary arterial pressure/mean systemic arterial pressure < 2/3) at the end of the implantation. The prolongation of ECMO support showed excellent survival rates, giving a survival benefit both with and without the inclusion of primary pulmonary hypertension (PPH) patients in the study cohort. Furthermore, they reported that half of the patients treated with post-operative ECMO had a negative chest X-ray with near normal tidal volumes at low ventilation pressure: this interesting evidence offers some considerations on PGD grading. Indeed, based on the past definition of PGD made by ISHLT[61], a grade 3 PGD was automatically assigned to patients on ECMO. This definition was revised in 2016, and patients who were still on ECMO at that time were classified as PGD ungradable. The conclusions drawn in this study suggested that the real function of those lungs did not correspond to a classic PGD 3. These observations were corroborated by short mechanical ventilation duration both in PPH and in non-PPH patients associating the concept of prolonged prophylactic ECMO with excellent outcomes.

**CONCLUSION**

The utilization of ECMO in LTx has multiple applications as it allows extension of transplant indications while decreasing the mortality rate in critically ill patients on the waiting list, when used as a bridge to LTx. An interesting field of investigation is the role of intra- and post-operative ECMO in reducing reperfusion injury and PGD. This evidence is needed to extend the use of ECMO as a routine procedure in the intra- and post-operative setting for LTx. Several randomized trials, correlated by histopathological analysis, are required to validate these findings.

**REFERENCES**

1 **Egan TM**, Murray S, Bustami RT, Shearon TH, McCullough KP, Edwards LB, Coke MA, Garrity ER, Sweet SC, Heiney DA, Grover FL. Development of the new lung allocation system in the United States. *Am J Transplant* 2006; **6**: 1212-1227 [PMID: 16613597 DOI: 10.1111/j.1600-6143.2006.01276.x]

2 **Yusen RD**, Shearon TH, Qian Y, Kotloff R, Barr ML, Sweet S, Dyke DB, Murray S. Lung transplantation in the United States, 1999-2008. *Am J Transplant* 2010; **10**: 1047-1068 [PMID: 20420652 DOI: 10.1111/j.1600-6143.2010.03055.x]

3 **Hayanga JA**, Lira A, Vlahu T, Yang J, Aboagye JK, Hayanga HK, Luketich JD, D'Cunha J. Lung Transplantation in Patients with High Lung Allocation Scores in the US: Evidence for the Need to Evaluate Score Specific Outcomes. *J Transplant* 2015; **2015**: 836751 [PMID: 26798504 DOI: 10.1155/2015/836751]

4 **Ius F**, Tudorache I, Warnecke G. Extracorporeal support, during and after lung transplantation: the history of an idea. *J Thorac Dis* 2018; **10**: 5131-5148 [PMID: 30233890 DOI: 10.21037/jtd.2018.07.43]

5 **Ius F**, Sommer W, Tudorache I, Avsar M, Siemeni T, Salman J, Molitoris U, Gras C, Juettner B, Puntigam J, Optenhoefel J, Greer M, Schwerk N, Gottlieb J, Welte T, Hoeper MM, Haverich A, Kuehn C, Warnecke G. Five-year experience with intraoperative extracorporeal membrane oxygenation in lung transplantation: Indications and midterm results. *J Heart Lung Transplant* 2016; **35**: 49-58 [PMID: 26496786 DOI: 10.1016/j.healun.2015.08.016]

6 **Hoetzenecker K**, Schwarz S, Muckenhuber M, Benazzo A, Frommlet F, Schweiger T, Bata O, Jaksch P, Ahmadi N, Muraközy G, Prosch H, Hager H, Roth G, Lang G, Taghavi S, Klepetko W. Intraoperative extracorporeal membrane oxygenation and the possibility of postoperative prolongation improve survival in bilateral lung transplantation. *J Thorac Cardiovasc Surg* 2018; **155**: 2193-2206.e3 [PMID: 29653665 DOI: 10.1016/j.jtcvs.2017.10.144]

7 **Dell'Amore A**, Schiavon M, Rea F. Central bicaval cannulation for extracorporeal membrane oxygenation support during double lung transplantation for primary pulmonary artery hypertension. *Artif Organs* 2019; **43**: 1112-1113 [PMID: 31321779 DOI: 10.1111/aor.13526]

8 **Reeb J**, Olland A, Massard G, Falcoz PE. Extracorporeal life support in thoracic surgery. *Eur J Cardiothorac Surg* 2018; **53**: 489-494 [PMID: 29340579 DOI: 10.1093/ejcts/ezx477]

9 **Biscotti M**, Bacchetta M. The "sport model": extracorporeal membrane oxygenation using the subclavian artery. *Ann Thorac Surg* 2014; **98**: 1487-1489 [PMID: 25282228 DOI: 10.1016/j.athoracsur.2014.02.069]

10 **Bazan VM**, Rodgers-Fischl P, Zwischenberger JB. Supportive Therapy: Extracorporeal Membrane Oxygenation. *Crit Care Clin* 2020; **36**: 517-529 [PMID: 32473696 DOI: 10.1016/j.ccc.2020.02.007]

11 **Matheis G**. New technologies for respiratory assist. *Perfusion* 2003; **18**: 245-251 [PMID: 14575413 DOI: 10.1191/0267659103pf684oa]

12 **Strueber M**, Hoeper MM, Fischer S, Cypel M, Warnecke G, Gottlieb J, Pierre A, Welte T, Haverich A, Simon AR, Keshavjee S. Bridge to thoracic organ transplantation in patients with pulmonary arterial hypertension using a pumpless lung assist device. *Am J Transplant* 2009; **9**: 853-857 [PMID: 19344471 DOI: 10.1111/j.1600-6143.2009.02549.x]

13 **Fischer S**, Simon AR, Welte T, Hoeper MM, Meyer A, Tessmann R, Gohrbandt B, Gottlieb J, Haverich A, Strueber M. Bridge to lung transplantation with the novel pumpless interventional lung assist device NovaLung. *J Thorac Cardiovasc Surg* 2006; **131**: 719-723 [PMID: 16515929 DOI: 10.1016/j.jtcvs.2005.10.050]

14 **Schellongowski P**, Riss K, Staudinger T, Ullrich R, Krenn CG, Sitzwohl C, Bojic A, Wohlfarth P, Sperr WR, Rabitsch W, Aigner C, Taghavi S, Jaksch P, Klepetko W, Lang G. Extracorporeal CO2 removal as bridge to lung transplantation in life-threatening hypercapnia. *Transpl Int* 2015; **28**: 297-304 [PMID: 25387861 DOI: 10.1111/tri.12486]

15 **Bartosik W**, Egan JJ, Wood AE. The Novalung interventional lung assist as bridge to lung transplantation for self-ventilating patients - initial experience. *Interact Cardiovasc Thorac Surg* 2011; **13**: 198-200 [PMID: 21543364 DOI: 10.1510/icvts.2011.266346]

16 **Del Sorbo L**, Pisani L, Filippini C, Fanelli V, Fasano L, Terragni P, Dell'Amore A, Urbino R, Mascia L, Evangelista A, Antro C, D'Amato R, Sucre MJ, Simonetti U, Persico P, Nava S, Ranieri VM. Extracorporeal Co2 removal in hypercapnic patients at risk of noninvasive ventilation failure: a matched cohort study with historical control. *Crit Care Med* 2015; **43**: 120-127 [PMID: 25230375 DOI: 10.1097/CCM.0000000000000607]

17 **Painvin GA**, Reece IJ, Cooley DA, Frazier OH. Cardiopulmonary allotransplantation, a collective review: experimental progress and current clinical status. *Tex Heart Inst J* 1983; **10**: 371-386 [PMID: 15226972]

18 **Jackson A**, Cropper J, Pye R, Junius F, Malouf M, Glanville A. Use of extracorporeal membrane oxygenation as a bridge to primary lung transplant: 3 consecutive, successful cases and a review of the literature. *J Heart Lung Transplant* 2008; **27**: 348-352 [PMID: 18342760 DOI: 10.1016/j.healun.2007.12.006]

19 **Vieth FJ**. Lung transplantation. *Transplant Proc* 1997; **9**: 203-208 [PMID: 325760]

20 Sequential bilateral lung transplantation for paraquat poisoning. A case report. The Toronto Lung Transplant group. *J Thorac Cardiovasc Surg* 1985; **89**: 734-742 [PMID: 3887042 DOI: 10.1016/S0022-5223(19)38729-X]

21 **Jurmann MJ**, Haverich A, Demertzis S, Schaefers HJ, Wagner TO, Borst HG. Extracorporeal membrane oxygenation as a bridge to lung transplantation. *Eur J Cardiothorac Surg* 1991; **5**: 94-7; discussion 98 [PMID: 2018660 DOI: 10.1016/1010-7940(91)90006-6]

22 **Weill D**, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, Lederer DJ, Mulligan MJ, Patterson GA, Singer LG, Snell GI, Verleden GM, Zamora MR, Glanville AR. A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. *J Heart Lung Transplant* 2015; **34**: 1-15 [PMID: 25085497 DOI: 10.1016/j.healun.2014.06.014]

23 **Abrams D**, Brodie D, Arcasoy SM. Extracorporeal Life Support in Lung Transplantation. *Clin Chest Med* 2017; **38**: 655-666 [PMID: 29128016 DOI: 10.1016/j.ccm.2017.07.006]

24 **Diaz-Guzman E,** Davenport DL, Zwischenberger JB, Hoopes CW. Lung function and ECMO after lung transplantation. *Ann Thorac Surg* 2012; **94:** 686-687 [PMID: 22818322 DOI: 10.1016/j.athoracsur.2011.12.014]

25 **Del Sorbo L**, Ranieri VM, Keshavjee S. Extracorporeal membrane oxygenation as "bridge" to lung transplantation: what remains in order to make it standard of care? *Am J Respir Crit Care Med* 2012; **185**: 699-701 [PMID: 22467804 DOI: 10.1164/rccm.201202-0193ED]

26 **Mason DP**, Thuita L, Nowicki ER, Murthy SC, Pettersson GB, Blackstone EH. Should lung transplantation be performed for patients on mechanical respiratory support? The US experience. *J Thorac Cardiovasc Surg* 2010; **139**: 765-773.e1 [PMID: 19931096 DOI: 10.1016/j.jtcvs.2009.09.031]

27 **Todd EM**, Biswas Roy S, Hashimi AS, Serrone R, Panchanathan R, Kang P, Varsch KE, Steinbock BE, Huang J, Omar A, Patel V, Walia R, Smith MA, Bremner RM. Extracorporeal membrane oxygenation as a bridge to lung transplantation: A single-center experience in the present era. *J Thorac Cardiovasc Surg* 2017; **154**: 1798-1809 [PMID: 29042051 DOI: 10.1016/j.jtcvs.2017.06.063]

28 **Yeo HJ**, Lee S, Yoon SH, Lee SE, Cho WH, Jeon D, Kim YS, Kim D. Extracorporeal Life Support as a Bridge to Lung Transplantation in Patients With Acute Respiratory Failure. *Transplant Proc* 2017; **49**: 1430-1435 [PMID: 28736018 DOI: 10.1016/j.transproceed.2017.02.064]

29 **Biscotti M**, Gannon WD, Agerstrand C, Abrams D, Sonett J, Brodie D, Bacchetta M. Awake Extracorporeal Membrane Oxygenation as Bridge to Lung Transplantation: A 9-Year Experience. *Ann Thorac Surg* 2017; **104**: 412-419 [PMID: 28242078 DOI: 10.1016/j.athoracsur.2016.11.056]

30 **Ko RE**, Lee JG, Kim SY, Kim YT, Choi SM, Kim DH, Cho WH, Park SI, Jo KW, Kim HK, Paik HC, Jeon K; Korean Organ Transplantation Registry Study Group. Extracorporeal membrane oxygenation as a bridge to lung transplantation: analysis of Korean organ transplantation registry (KOTRY) data. *Respir Res* 2020; **21**: 20 [PMID: 31931798 DOI: 10.1186/s12931-020-1289-2]

31 **Tipograf Y**, Salna M, Minko E, Grogan EL, Agerstrand C, Sonett J, Brodie D, Bacchetta M. Outcomes of Extracorporeal Membrane Oxygenation as a Bridge to Lung Transplantation. *Ann Thorac Surg* 2019; **107**: 1456-1463 [PMID: 30790550 DOI: 10.1016/j.athoracsur.2019.01.032]

32 **Hakim AH**, Ahmad U, McCurry KR, Johnston DR, Pettersson GB, Budev M, Murthy S, Blackstone EH, Tong MZ. Contemporary Outcomes of Extracorporeal Membrane Oxygenation Used as Bridge to Lung Transplantation. *Ann Thorac Surg* 2018; **106**: 192-198 [PMID: 29559375 DOI: 10.1016/j.athoracsur.2018.02.036]

33 **Benazzo A**, Schwarz S, Frommlet F, Schweiger T, Jaksch P, Schellongowski P, Staudinger T, Klepetko W, Lang G, Hoetzenecker K; Vienna ECLS Program. Twenty-year experience with extracorporeal life support as bridge to lung transplantation. *J Thorac Cardiovasc Surg* 2019; **157**: 2515-2525.e10 [PMID: 30922636 DOI: 10.1016/j.jtcvs.2019.02.048]

34 **Hoetzenecker K**, Donahoe L, Yeung JC, Azad S, Fan E, Ferguson ND, Del Sorbo L, de Perrot M, Pierre A, Yasufuku K, Singer L, Waddell TK, Keshavjee S, Cypel M. Extracorporeal life support as a bridge to lung transplantation-experience of a high-volume transplant center. *J Thorac Cardiovasc Surg* 2018; **155**: 1316-1328.e1 [PMID: 29248282 DOI: 10.1016/j.jtcvs.2017.09.161]

35 **Ius F**, Natanov R, Salman J, Kuehn C, Sommer W, Avsar M, Siemeni T, Bobylev D, Poyanmehr R, Boethig D, Optenhoefel J, Schwerk N, Haverich A, Warnecke G, Tudorache I. Extracorporeal membrane oxygenation as a bridge to lung transplantation may not impact overall mortality risk after transplantation: results from a 7-year single-centre experience. *Eur J Cardiothorac Surg* 2018; **54**: 334-340 [PMID: 29444222 DOI: 10.1093/ejcts/ezy036]

36 **Polastri M**, Loforte A, Dell'Amore A, Nava S. Physiotherapy for Patients on Awake Extracorporeal Membrane Oxygenation: A Systematic Review. *Physiother Res Int* 2016; **21**: 203-209 [PMID: 26274362 DOI: 10.1002/pri.1644]

37 **Diaz-Guzman E**, Hoopes CW, Zwischenberger JB. The evolution of extracorporeal life support as a bridge to lung transplantation. *ASAIO J* 2013; **59**: 3-10 [PMID: 23271390 DOI: 10.1097/MAT.0b013e31827461c2]

38 **Machuca TN**, Collaud S, Mercier O, Cheung M, Cunningham V, Kim SJ, Azad S, Singer L, Yasufuku K, de Perrot M, Pierre A, McRae K, Waddell TK, Keshavjee S, Cypel M. Outcomes of intraoperative extracorporeal membrane oxygenation versus cardiopulmonary bypass for lung transplantation. *J Thorac Cardiovasc Surg* 2015; **149**: 1152-1157 [PMID: 25583107 DOI: 10.1016/j.jtcvs.2014.11.039]

39 **Biscotti M**, Yang J, Sonett J, Bacchetta M. Comparison of extracorporeal membrane oxygenation versus cardiopulmonary bypass for lung transplantation. *J Thorac Cardiovasc Surg* 2014; **148**: 2410-2415 [PMID: 25444203 DOI: 10.1016/j.jtcvs.2014.07.061]

40 **Marczin N**, Royston D, Yacoub M. Pro: lung transplantation should be routinely performed with cardiopulmonary bypass. *J Cardiothorac Vasc Anesth* 2000; **14**: 739-745 [PMID: 11139121 DOI: 10.1053/jcan.2000.18592]

41 **Hoetzenecker K**, Benazzo A, Stork T, Sinn K, Schwarz S, Schweiger T, Klepetko W; Vienna Lung Transplant Group. Bilateral lung transplantation on intraoperative extracorporeal membrane oxygenator: An observational study. *J Thorac Cardiovasc Surg* 2020; **160**: 320-327.e1 [PMID: 31932054 DOI: 10.1016/j.jtcvs.2019.10.155]

42 **Nazarnia S**, Subramaniam K. Pro: Veno-arterial Extracorporeal Membrane Oxygenation (ECMO) Should Be Used Routinely for Bilateral Lung Transplantation. *J Cardiothorac Vasc Anesth* 2017; **31**: 1505-1508 [PMID: 27591909 DOI: 10.1053/j.jvca.2016.06.015]

43 **Glorion M**, Mercier O, Mitilian D, De Lemos A, Lamrani L, Feuillet S, Pradere P, Le Pavec J, Lehouerou D, Stephan F, Savale L, Fabre D, Mussot S, Fadel E. Central versus peripheral cannulation of extracorporeal membrane oxygenation support during double lung transplant for pulmonary hypertension. *Eur J Cardiothorac Surg* 2018; **54**: 341-347 [PMID: 29528384 DOI: 10.1093/ejcts/ezy089]

44 **Cosgun T**, Tomaszek S, Opitz I, Wilhelm M, Schuurmans MM, Weder W, Inci I. Single-center experience with intraoperative extracorporeal membrane oxygenation use in lung transplantation. *Int J Artif Organs* 2017: 0 [PMID: 29027193 DOI: 10.5301/IJAO.5000645]

45 **Pettenuzzo T**, Faggi G, Di Gregorio G, Schiavon M, Marulli G, Gregori D, Rea F, Ori C, Feltracco P. Blood Products Transfusion and Mid-Term Outcomes of Lung Transplanted Patients Under Extracorporeal Membrane Oxygenation Support. *Prog Transplant* 2018; **28**: 314-321 [PMID: 29879861 DOI: 10.1177/1526924818765816]

46 **Dell'Amore A**, Campisi A, Congiu S, Mazzarra S, Pastore S, Dolci G, Baiocchi M, Frascaroli G. Extracorporeal life support during and after bilateral sequential lung transplantation in patients with pulmonary artery hypertension. *Artif Organs* 2020; **44**: 628-637 [PMID: 31885090 DOI: 10.1111/aor.13628]

47 **Halldorsson A**, Kronon M, Allen BS, Bolling KS, Wang T, Rahman S, Feinberg H. Controlled reperfusion after lung ischemia: implications for improved function after lung transplantation. *J Thorac Cardiovasc Surg* 1998; **115**: 415-24; discussion 424-5 [PMID: 9475537 DOI: 10.1016/S0022-5223(98)70286-7]

48 **Christie JD**, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Dobbels F, Kirk R, Rahmel AO, Stehlik J, Hertz MI; International Society of Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. *J Heart Lung Transplant* 2012; **31**: 1073-1086 [PMID: 22975097 DOI: 10.1016/j.healun.2012.08.004]

49 **Gulack BC**, Hirji SA, Hartwig MG. Bridge to lung transplantation and rescue post-transplant: the expanding role of extracorporeal membrane oxygenation. *J Thorac Dis* 2014; **6**: 1070-1079 [PMID: 25132974 DOI: 10.3978/j.issn.2072-1439.2014.06.04]

50 **Abrams D**, Brodie D. Emerging indications for extracorporeal membrane oxygenation in adults with respiratory failure. *Ann Am Thorac Soc* 2013; **10**: 371-377 [PMID: 23952860 DOI: 10.1513/AnnalsATS.201305-113OT]

51 **Abrams D**, Brodie D, Combes A. What is new in extracorporeal membrane oxygenation for ARDS in adults? *Intensive Care Med* 2013; **39**: 2028-2030 [PMID: 23903779 DOI: 10.1007/s00134-013-3035-4]

52 **Levi-Schaffer F**, Gare M, Shalit M. Unresponsiveness of rat peritoneal mast cells to immunologic reactivation. *J Immunol* 1990; **145**: 3418-3424 [PMID: 17000310 DOI: 10.1016/j.jtcvs.2006.06.010]

53 **Marasco SF**, Vale M, Preovolos A, Pellegrino V, Lee G, Snell G, Williams T. Institution of extracorporeal membrane oxygenation late after lung transplantation - a futile exercise? *Clin Transplant* 2012; **26**: E71-E77 [PMID: 22151107 DOI: 10.1111/j.1399-0012.2011.01562.x]

54 **Tudorache I**, Sommer W, Kühn C, Wiesner O, Hadem J, Fühner T, Ius F, Avsar M, Schwerk N, Böthig D, Gottlieb J, Welte T, Bara C, Haverich A, Hoeper MM, Warnecke G. Lung transplantation for severe pulmonary hypertension--awake extracorporeal membrane oxygenation for postoperative left ventricular remodelling. *Transplantation* 2015; **99**: 451-458 [PMID: 25119128 DOI: 10.1097/TP.0000000000000348]

55 **Porteous MK**, Ky B, Kirkpatrick JN, Shinohara R, Diamond JM, Shah RJ, Lee JC, Christie JD, Kawut SM. Diastolic Dysfunction Increases the Risk of Primary Graft Dysfunction after Lung Transplant. *Am J Respir Crit Care Med* 2016; **193**: 1392-1400 [PMID: 26745666 DOI: 10.1164/rccm.201508-1522OC]

56 **Kevorkian G**. Adverse sequelae with combined use of beta-blockers and epinephrine. *Gen Dent* 1987; **35**: 298-300 [PMID: 28950326 DOI: 10.1093/ejcts/ezx212]

57 **Mulvihill MS**, Yerokun BA, Davis RP, Ranney DN, Daneshmand MA, Hartwig MG. Extracorporeal membrane oxygenation following lung transplantation: indications and survival. *J Heart Lung Transplant* 2017; **37**: 259-267 [PMID: 28712677 DOI: 10.1016/j.healun.2017.06.014]

58 **Song JH**, Park JE, Lee JG, Lee CY, Nam KS, Suh JW, Kim A, Lee SH, Joo HC, Youn YN, Kim SY, Park MS, Paik HC. Outcomes of perioperative extracorporeal membrane oxygenation use in patients undergoing lung transplantation. *J Thorac Dis* 2017; **9**: 5075-5084 [PMID: 29312713 DOI: 10.21037/jtd.2017.10.142]

59 **Moon S**, Park MS, Lee JG, Jung JY, Kang YA, Kim YS, Kim SK, Chang J, Paik HC, Kim SY. Risk factors and outcome of primary graft dysfunction after lung transplantation in Korea. *J Thorac Dis* 2016; **8**: 3275-3282 [PMID: 28066607 DOI: 10.21037/jtd.2016.11.48]

60 **Grimm JC**, Valero V 3rd, Kilic A, Magruder JT, Merlo CA, Shah PD, Shah AS. Association Between Prolonged Graft Ischemia and Primary Graft Failure or Survival Following Lung Transplantation. *JAMA Surg* 2015; **150**: 547-553 [PMID: 25874575 DOI: 10.1001/jamasurg.2015.12]

61 **Christie JD**, Carby M, Bag R, Corris P, Hertz M, Weill D; ISHLT Working Group on Primary Lung Graft Dysfunction. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation. *J Heart Lung Transplant* 2005; **24**: 1454-1459 [PMID: 16210116 DOI: 10.1016/j.healun.2004.11.049]

**Footnotes**

**Conflict-of-interest statement:** Authors have nothing to disclose.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** March 4, 2021

**First decision:** March 31, 2021

**Article in press:** May 25, 2021

**Specialty type:** Transplantation

**Country/Territory of origin:** Italy

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B


Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Chambers DJ, Dimopoulos S **S-Editor:** Liu M **L-Editor:** Webster JR **P-Editor:** Yuan YY

**Figure Legends**



**Figure 1 Different extra-corporeal membrane oxygenation configurations.** A: Veno-venous extra-corporeal membrane oxygenation (ECMO) with jugular cannulation; B: Veno-arterial ECMO with peripheral cannulation, with the cannula for distal perfusion of the leg; C: Veno-arterial ECMO with central cannulation, the blood is drained from the right atrium and reinfused into the aorta; D: Central bicaval veno-arterial ECMO configuration.

**Table 1 Different ECMO configurations in lung transplantation**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **ECMO configuration** | **Cannulation** | **Support provided** | **Patient condition** | **Utilizazion in LTx** |
| VV | Peripheral (double lumen cannula in the SVC *via* the jugular or subclavian vein or a single lumen cannula in the femoral vein or jugular and femoral veins) | Only respiratory | Hypoxemia | Bridge to transplantation;  post-operative period |
| VA | Peripheral (femoral vessels; jugular/subclavian vein and subclavian artery) | Respiratory + circulatory | Hypoxemia and cardiac failure | Bridge to transplantation;  intra-operative;  post-operative period |
| Central (from right atrium to aorta) |
| VVA | Same as VV ECMO + an additional cannula in the subclavian artery | Respiratory + circulatory | Severe right heart dysfunction with hypoxemia | Bridge to transplantation;  intra-operative;  post-operative period |

VV: Veno-venous; VA: Veno-arterial; VVA: Veno-venous arterial; ECMO: Extracorporeal membrane oxygenation, LTx: Lung transplantation, SVC: Superior vena cava.

**Table 2 Outcomes of the main studies on**  **extracorporeal membrane oxygenation as a bridge to lung transplantation**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Number of patients** | **Median duration of ECMO** | **Mode of ECMO** | **Complications** | **Successful bridge (%)** | **In-hospital mortality** | **1-yr survival** | **3-yr survival** |
| Tipograf *et al*[31], 2019 | 121 | 12 d | VV (52%) | ECMO site 11% | 59% | 9% | 88% | 83% |
| VA (43%) | Renal 8.3% |
| VAV (2.5%) | Vascular 12% |
| RA-LA (1.6%) | Cardiac arrest 9.9% |
| PA-LA (0.8%) | Cerebrovascular 12% |
| Biscotti *et al*[29], 2017 | 72 | 12 d | VV (62.5%) | ECMO site 15.2% | 55.6% | 7.5% | 90.3% | NR |
| VA (31.9%) | Renal 8.3% |
| VAV (4.2%) | Vascular 15.2% |
| PA-LA (1.4%) | Cerebrovascular 5.5% |
| Hakim *et al*[32], 2018 | 30 | 8 d | VV (80%) | Bleeding 33% | 87% | NR | 85% | 80% |
| VA (16.7%) | Cardiac arrest 13% |
| VVA (3.3%) | Cannula fracture 3% |
|  | Thrombocytopenia 23% |
|  | Needing paralytics 27% |
| Benazzo *et al*[33], 2019 | 120 | 5 d | VV 34% | Vascular 3.3% | 80% | 23.3% | 69% | NR |
| VA 30% | Cannula related 6.6% |
| iLA 21.7% | IDC 0.8% |
| VAV 0.8% |  |
| Other 13.3% |  |
| Todd *et al*[27], 2017 | 12 | 2 d | VV 92% | NR | 100% | 0% | 100% | NR |
| VA 8% |
| Yeo *et al*[28], 2017 | 19 | 17.5 d | VV 79% | Bleeding 26% | 73.7% | 42% | 57.9% | NR |
| VA 16% | Infections 10.5% |
| VAV 5% |  |
| Ko *et al*[30], 2020 | 27 | 11 d | VV 89% | Bleeding 46.7% | 100% | 25.9% | 75% | 70% |
| VAV 7.4% | Infections 26.7% |
| VA 3.7% | Airway 13.3% |
| Hoetzenecker *et al*[34], 2018 | 71 | 10 d | VV 42.3% | Cerebrovascular 4.2% | 88.7% | NR | 70% | 63% |
| VA 9.9% | Renal 31.7% |
| PA-LA 12.7% | Bleeding 34.9% |
| Other 33.8% |  |
| Ius *et al*[35], 2018 | 87 | 9 d | VV 73% | Bleeding 21% | 78% | 15% | 79% | NR |
| VA 37% | Renal 27% |
|  | Vascular 10% |
|  | Cerebrovascular 2% |
|  | Atrial fibrillation 13% |

ECMO: Extracorporeal membrane oxygenation; VV: Veno-venous; VA: Veno-arterial; VAV: Veno-arterial-venous; PA-LA: Pulmonary artery-left atrium; RA-LA: Right atrium-left atrium; NR: Not reported; iLA: Interventional Lung Assist.

**Table 3 Outcomes of the main studies on extracorporeal membrane oxygenation for intraoperative support during lung transplantation**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **No. of patients** | **Type of ECMO** | **Complications** | **PGD rates** | **In hospital mortality** | **1-yr survival** | **3-yr survival** |
| Glorion *et al*[43], 2018 | 103 | pECMO 47.5% | Rethoracotomy for bleeding 21.4% | 72 h grade 1-2: 70.8% | 12.6% | 82.4% | 65% |
| cECMO 52.5% | Chest infections 5.8% | 72 h grade 3: 33% |
|  | Deep vein thrombosis 18.4% |  |
|  | Lower limb ischemia 6.8% |  |
| Pettenuzzo *et al*[45], 2018 | 15 | NR | Bleeding/surgical revision 26.6% | NR | 13.3% | NR | NR |
| Pulmonary thromboembolism 6.7% |
| Cardiogenic shock 13.3% |
| Cerebrovascular events 6.7% |
| Sepsis with MOF 6.7% |
| Deep vein thrombosis 26.7% |
| Hoetzenecker *et al*[6], 2018 | 343 | cECMO 100% | Revision surgery 35% | 72 h grade 0: 87.5% | NR | 91% | 85% |
| Leg ischemia 0.6% | 72 h grade 1: 5.4% |
| Thromboembolic events 1.4% | 72 h grade 2: 3.9% |
|  | 72 h grade 3: 3.3% |
| Cosgun *et al*[44], 2017 | 134 | NR | Lymphocele 10.4% | 48 h or 72 h grade 2 or 3: 7.3% | NR | 84.2% | 60% |
| Limb ischemia 0.7% |
| Revision for hemothorax 12% |
| Local bleeding 0.7% |
| Local infection 0.7% |
| Ius *et al*[4], 2018 | 281 | NR | Rethoracotomy for bleeding 17.8% | 24 h grade 2-3: 31.3% | NR | NR | 74% |
| Cerebrovascular events 1.8% | 48 h grade 2-3: 35.2% |
| Vascular complications 9.6% | 72 h grade 2-3: 28.8% |
| Hoetzenecker *et al*[41], 2020 | 159 | cECMO 100% | Wound infections 8.2% | Grade 0: 48.4% | NR | 86% | NR |
| Evacuation of hemothorax 8.2% | Grade 1: 4.4% |
| Thromboembolic events 0% | Grade 2: 3.1% |
| Local bleeding 0% | Grade 3: 2.5% |
| Local infection 3.2% | Ungrad: 3.1% |
| Dell’Amore *et al*[46], 2020 | 38 | cECMO 76% | Evacuation of hemothorax 16% | 72 h grade 3: 16% | 18% | 76% | 69% |
| CPB 24% | Acute renal failure 21% |
|  | Pneumonia 29% |

ECMO: Extracorporeal membrane oxygenation; MOF: Multiorgan failure; NR: not reported; c: Central; p: Peripheral; Ungrad: Ungradable; CPB: Cardiopulmonary bypass; PGD: Primary graft dysfunction

**Table 4 Outcomes of the main studies on prolonged or de novo secondary extracorporeal membrane oxygenation implant after lung transplantation**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **Number of patients** | **Type of post-op ECMO** | **Median time from LTx to secondary ECMO** | **Weaning of second ECMO (%)** |
| Mulvihill *et al*[57], 2017 | 107 | De novo 100% | 3 d | NR |
| Song *et al*[58], 2017 | 73 | De novo 25% | 26 d | 50% |
| Prolonged 75% |
| Hoetzenecker *et al*[6], 2018 | 123 | Prolonged 100% | **/** | **/** |

ECMO: Extracorporeal membrane oxygenation; LTx: Lung transplantation.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**